Patient Assistance Programs
Neulasta®, NEUPOGEN® and You 

Most insurers require patients to share in the cost of their medical care. When your physician prescribes Neulasta® or NEUPOGEN® for you, you should expect to pay a part of the therapy's cost.

This may take the form of:
  • Deductibles - fixed annual payments you must make before your insurer reimburses for additional care (for example, the first $200 of medical bills)
  • Coinsurance/copayment -- an ongoing financial responsibility either in the form of a percent (coinsurance) or a flat amount (copayment) of your medical bill

However, most payors limit the out-of-pocket costs for a patient. This limit is often referred to as an out-of-pocket maximum or a stop-loss mechanism. Private payors may have specific coverage policies for injectable medications.

Read your insurance plan handbook to understand how much of the cost of Neulasta® or NEUPOGEN® you will have to pay.

The information provided in this section is of a general nature and for informational purposes only. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters and appropriate coding for a particular patient and/or procedure is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

 

 

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

© 2007 Amgen All Rights Reserved. Prescribing Information for Neulasta®